Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037326 | 1.00 | TLR7 (0.48) | TLR7TLR8MAPTL3MBTL1 | |
| SCHEMBL20212312 | 0.91 | TLR7 (0.50) | TLR7MAPT | |
| SCHEMBL30037453 | 0.91 | TLR7 (0.50) | TLR7MAPT | |
| SCHEMBL30035518 | 0.91 | TLR7 (0.50) | TLR7MAPT | |
| SCHEMBL22508906 | 0.89 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL30036469 | 0.88 | NPSR1 (0.51) | TLR7TLR8MAPT | |
| SCHEMBL853999 | 0.88 | NPSR1 (0.51) | TLR7TLR8MAPT | |
| SCHEMBL16624314 | 0.88 | TLR7 (0.41) | TLR7MAPTL3MBTL1 | |
| SCHEMBL4215783 | 0.86 | TLR7 (0.47) | TLR7MAPT | |
| SCHEMBL4214528 | 0.85 | LMNA (0.46) | TLR7MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12077510-B2 | Carboxylic acid compounds | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| CN-102482233-A | Novel pyrimidine derivatives and their use in the treatment of cancer and other diseases | ASTRAZENECA AB SE | 2012-05-30 | — | — | CN | disclosed |
| WO-2012066336-A1 | BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066336-A1 | BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| CN-101925584-A | Pyrimidine Derivatives for the Treatment of Asthma, COPD, Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis, Cancer, Hepatitis B, Hepatitis C, HIV, HPV, Bacterial Infections and Skin Diseases | ASTRAZENECA AB | 2010-12-22 | — | — | CN | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | TLR7, TLR9, STING1 | TLR7 1/4885TLR8 8/4885MAPT 4233/4885 |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885MAPT 2971/4885 |
| US-12077510-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885MAPT 4403/4885 |
| US-11299465-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885MAPT 4403/4885 |
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TLR7 2/4885TLR8 16/4885MAPT 4286/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | TLR7 3271/4885TLR8 4435/4885MAPT 2803/4885 |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885MAPT 4403/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TLR7 1/4885TLR8 9/4885MAPT 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.